<DOC>
	<DOCNO>NCT01605383</DOCNO>
	<brief_summary>The present study evaluate effect XCEL-MT-OSTEO-ALPHA osteonecrosis femoral head comparison standard treatment isolate core decompression . XCEL-MT-OSTEO-ALPHA tissue engineering product compose `` ex-vivo '' expand autologous mesenchymal stem cell fix allogenic bone tissue . The work hypothesis proposes tissue engineering valid useful technique achieve bone regeneration , avoid progression collapse femoral head .</brief_summary>
	<brief_title>Mesenchymal Stem Cells Osteonecrosis Femoral Head</brief_title>
	<detailed_description>Prospective , open-label blind assessor , randomize , parallel , single-dose phase I-II clinical trial 24 patient affected osteonecrosis femoral head ARCO grade I II enter trial primary objective assess feasibility safety `` ex-vivo '' expand autologous mesenchymal stem cell fix allogenic bone tissue osteonecrosis femoral head . Secondary objective assess efficacy implantation imaging ( magnetic resonance imaging ) clinical questionnaire ( pain visual analogue scale , quality life SF-36 WOMAC Index ) . Patients randomize one two treatment arm ( core decompression tissue engineering product compose `` ex-vivo '' expand autologous mesenchymal stem cell fix allogenic bone tissue standard treatment isolate core decompression ) . Thereafter , patient follow 12 month .</detailed_description>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Osteonecrosis</mesh_term>
	<mesh_term>Femur Head Necrosis</mesh_term>
	<criteria>18 50 year age ( male female ) Osteonecrosis hip ARCO grade I II Abscence systemic local infection Laboratory test relevant abnormal finding contraindicate surgery . Informed Consent Form sign The patient able understand nature study Osteonecrosis hip secondary femoral neck fracture Patients close cartilage Surgical implant femoral head Septic arthritis Patients severe renal insufficiency Patients expect liver transplantation Positive serology HIV1 HIV2 , Hepatitis B ( HBsAg ) , Hepatitis C ( AntiHCVAb ) Syphilis . Pregnant woman intend become pregnant , breath feeding Neoplasia within previous 5 year , without remission Immunosuppressive state The patient legally dependent Participation another clinical trial treat investigational medicinal product previous 30 day Cardiac pacemaker , allergy contrast condition contraindicate MRI contrast agent Other pathologic condition circumstance difficult participation study accord medical criterion The patient accept followedup period thar could exceed clinical trial length</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Avascular Necrosis Femur Head</keyword>
	<keyword>Osteonecrosis hip</keyword>
	<keyword>Osteonecrosis femoral head</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Bone marrow</keyword>
	<keyword>Tissue engineering</keyword>
	<keyword>Bone Diseases</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
</DOC>